Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity
The DOI matches its Crossref record.
Abstract
Modern societies have moved from famine to feast and obesity and its co-morbidities now sweep the world as a global epidemic. Numerous scientific laboratories and pharmaceutical companies have taken the challenge and are now exploiting novel molecular targets for treatment of obesity. The pre-proglucagon system constitutes interesting candidates as potential targets for new anti-obesity drugs. In the periphery, pre-proglucagon derived peptides, Glucagon-Like Peptide-1 (GLP-1), Glucagon-Like Peptide-2 (GLP-2) and oxyntomodulin (OXM) are involved in a wide variety of physiological functions, including glucose homeostasis, gastric emptying, intestinal growth, insulin secretion as well as the regulation of food intake. Peripheral administration of GLP-1 derivatives and analogues to both rodents and man have shown promising effects on food intake and body weight suggesting that such therapies constitute potential anti-obesity treatment. In the central nervous system, pre-proglucagon and hence GLP-1, GLP-2 and OXM are exclusively found in a small population of nerve cells in the nucleus of the solitary tract. These constitute a neural pathway linking the "viscero-sensory" brainstem to hypothalamic nuclei involved in energy homeostasis. Intracerebroventricular administration of all of the three derived peptides robustly decrease food intake. It is evident that central GLP-1 agonism probably in combination with GLP-2 and/or OXM agonism constitute a potential pharmacological tool to reduce food intake and maybe also enhance energy expenditure. This and other aspects of the current state of the role of central pre-proglucagon in energy homeostasis are reviewed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experiments on mice have shown that intraventricular administration of GLP-1, GLP-2, and OXM could significantly reduce food intake (25, 26).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [25]
In the citing paper
“Central GLP-1 activation may be combined with GLP-2 and/or OXM activation to form a potential pharmacological tool to reduce meal intake and possibly increase energy consumption (25, 27).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [25]
Citations
Cited by
Impact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
Gastrointestinal hormones and food intake
Strader, A. D., & Woods, S. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.043 · Cited by 447
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G. S., Chowansky, A., Zimmer, D., De Jonghe, B. C., Kanoski, S. E., Grill, H. J., & Bence, K. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.001 · Cited by 234
“Pharmacological agents targeting the peripheral GLP-1 system are used to treat T2DM and may also prove to be efficacious in 324 Cell Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc. obesity treatment (Hayes et al., 2010a; Holst, 2007; Larsen et al., 2003; Lovshin and Drucker, 2009).”
The glucagonoma syndrome and necrolytic migratory erythema: a clinical review
van Beek, A., de Haas, E., van Vloten, W., Lips, C., Roijers, J., & Canninga-van Dijk, M. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510531 · Cited by 202
Metadata
- Authors
- Larsen, P., Vrang, N., & Tang-Christensen, M.
- ORCID
- Vrang, Niels
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-07-01
- Volume
- 9
- Issue
- 17
- Pages
- 1373-1382
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2166985274
- Cited by
- 24
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2016: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, glucagon-like peptide-2, oxyntomodulin, obesity, anti-obesity drugs, nucleus tractus solitarius, central nervous system, dietary intake, energy homeostasis, hypothalamus, glucose homeostasis, insulin secretion, gastric emptying, energy expenditure
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Behavior, Animal, Central Nervous System, Eating, Glucagon-Like Peptides, Glucagon, Humans, Obesity, Peptide Fragments, Peptides, Protein Precursors, Receptors, Glucagon, Glucagon-Like Peptide 1, Proglucagon, Glucagon-Like Peptide 2, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity. https://app.cochat.ai/papers/10.2174/1381612033454775
- The paper
- Larsen, P., Vrang, N., & Tang-Christensen, M. (2003). Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity. Current Pharmaceutical Design. https://doi.org/10.2174/1381612033454775
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.